Form 4: Abbott SVP Shroff Reports Routine Share Dispositions

Abbott Laboratories Senior Vice President Eric Shroff reported the disposition of 2,093 common shares through tax withholding and an open market sale.

Summary

• Eric Shroff, Senior Vice President of Abbott Laboratories, reported changes in his beneficial ownership of common shares.
• On February 27, 2026, Shroff disposed of 1,384 common shares at a price of $116.26 per share. This transaction was coded 'F', indicating payment of tax liability by withholding securities.
• On March 2, 2026, Shroff disposed of an additional 709 common shares at a price of $115.58 per share. This transaction was coded 'S', indicating an open market or private sale.
• Following these transactions, Shroff beneficially owns 39,164 common shares of Abbott Laboratories.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider share dispositions, including tax-related sales and an open market sale, all conducted under a pre-arranged 10b5-1 plan.

Positives

• Transactions were conducted under a Rule 10b5-1(c) plan, indicating pre-planned sales and reducing concerns about opportunistic insider trading.

Negatives

• Senior Vice President Eric Shroff sold a total of 2,093 common shares, reducing his direct beneficial ownership.

Industry Context

StockSavvy.ai notes that routine insider transactions, especially those under a 10b5-1 plan, are common across industries and typically do not signal significant shifts in company performance or strategy. These transactions are often for personal financial planning or tax obligations.

Comparison to Industry Standards

• StockSavvy.ai observes that the reported share dispositions by a Senior Vice President at Abbott Laboratories are typical for executive compensation and personal financial management within large pharmaceutical and medical device companies.
• Similar routine sales are seen at peers like Johnson & Johnson (JNJ) or Medtronic (MDT) where executives periodically sell shares for liquidity or tax purposes, often under pre-arranged 10b5-1 plans.
• The volume of shares sold (2,093 shares) is relatively small compared to the executive's remaining holdings (39,164 shares) and the company's overall market capitalization, aligning with standard practices for managing equity compensation.

Related Party Transactions

• The reported share dispositions by Senior Vice President Eric Shroff are considered related-party transactions as they involve an insider of Abbott Laboratories.

Stakeholder Impact

• Shareholders: Minimal direct impact as the transactions are routine and relatively small, conducted under a 10b5-1 plan. Provides transparency regarding insider holdings.
• Employees, Customers, Suppliers, Creditors: No direct impact from these routine insider share dispositions.

Key Dates

Recommendation

The filing details routine insider share dispositions by a Senior Vice President, including sales for tax purposes and an open market sale, all executed under a Rule 10b5-1 plan. These transactions are not indicative of a change in the company's fundamental outlook or a lack of confidence from management, but rather represent standard personal financial planning. Therefore, the filing itself does not provide a basis for a change in investment thesis, suggesting a "hold" recommendation for existing investors.

Keywords

Abbott Laboratories, ABT, Form 4, Insider Trading, Beneficial Ownership, Eric Shroff, Share Disposition, Rule 10b5-1, Senior Vice President